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Opinion statement
Migraine is a very disabling disorder with severe impact on patients’ lives and substantive
costs to society in terms of healthcare costs and lost productivity. Prevention is a key
component of migraine therapy, and while numerous preventive options exist, each is
burdened by either troublesome side effects or insufficient efficacy. All migraine preven-
tives currently in clinical use were licensed for other purposes and, by chance, have
efficacy against migraine. As our understanding of migraine has evolved, calcitonin
gene-related peptide (CGRP) has moved to the forefront as a neuropeptide central to
migraine pathophysiology. Six small molecule CGRP receptor antagonists were shown to be
effective for acute treatment of migraine; two were stopped for hepatotoxicity or one for
formulation concern issues and one is now in phase III. Monoclonal antibodies against
CGRP or the CGRP receptor have a longer duration of action and have been investigated for
migraine prevention. Four are in development and three have completed phase II and one
phase III trials; every reported study has been positive. Furthermore, no safety issues have
arisen to date, including hepatic or cardiovascular effects, and initial tolerability appears
to be excellent. Monoclonal antibodies antagonizing the CGRP pathway represent a novel
approach to prevention: a mechanism-specific migraine-targeted therapy. While we must
await the results of all the phase III trials, cautious excitement seems warranted as we
enter a new era of better tolerated, well-understood, bespoke migraine treatment for this
common and disabling neurological disorder.
Introduction
Migraine is one of the most prevalent and disabling
disorders in the world, yet its pathophysiology remains
incompletely understood [1]. Perhaps relating to this,
no preventive treatments that are currently in clinical use
were developed specifically for migraine [2]. For acute
treatment, the only class of agents developed specifically
for migraine, the triptans, was in fact thought to act via
its vasoconstrictive properties [3] based on the prevail-
ing view at the time that migraine was a vascular disor-
der [4]. It is now clear that vasodilation is neither neces-
sary nor sufficient for migraine pain, and migraine is
now understood to be a complex neuronal disorderwith
vascular epiphenomenon [5••].
The need for improved preventive treatments for
migraine is apparent: in the 2015 Global Burden of
Disease Study, migraine was the seventh leading cause
of disability globally and the leading neurological cause
of disability, accounting for over half of the years lost to
disability from all neurological disorders [6]. In the USA,
the estimated direct healthcare expenditure on migraine
is approximately $9 billion per year [7] with indirect
costs due to lost productivity doubling that figure [8].
Although numerous preventive treatment options exist
[2], their utility is often limited by intolerable side effects
such as cognitive slowing, drowsiness, or weight gain In
general, patient adherence is low due to such side effects
or insufficient efficacy [9, 10]
Research is ongoing to address this unmet need for
better prevention with fewer side effects. Advances in
our understanding of migraine pathophysiology have
led to new approaches such as neuromodulation and
new pharmacologic targets [11, 12], and perhaps none
have been as promising as calcitonin gene-related pep-
tide (CGRP).
Calcitonin gene-related peptide
CGRP is a 37-amino acid neuropeptide that is widely distributed throughout
the central and peripheral nervous systems [13, 14]. CGRP is present in sensory
neurons, including in the trigeminal ganglion and nerve endings as well as
dorsal root ganglia [15••]. CGRP has been localized in unmyelinated C fibers
and small myelinated Aδ fibers, which are involved in pain transmission, and is
co-expressed with serotonin 5-HT1B and 5-HT1D receptors [16, 17]. Immuno-
histochemistry studies in rats have shown CGRP is present centrally in brain
structures including the hypothalamus, thalamus, and cerebellum [18], and in
humans, CGRP binds densely in the cerebellum [19].
CGRP exists in α and β isoforms. The main isoform expressed in the
trigeminovascular system and in the brain is αCGRP, which is formed from
alternative splicing of the calcitonin gene. The β isoform is transcribed from a
different gene and differs from αCGRP by three amino acids. It is expressed
primarily in the enteric nervous system where it has distinct physiologic func-
tions such as inhibiting gastric acid secretion [18].
CGRP binds to a G-protein coupled receptor formed by two subunits:
calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein
1 (RAMP1) [20]. Outside of the nervous system, the CGRP receptor is also
found throughout the arterial system in the smoothmuscle cell layer, including
the cardiovascular and cerebrovascular systems, as well as in the adrenal glands,
kidneys, and pancreas [16, 21].
In addition to being a potent vasodilator [22], evidence suggests that CGRP
plays an important role in migraine pathophysiology. During spontaneous
migraine attacks, CGRP concentrationsmeasured from the external jugular vein
rise [23] and CGRP serum levels decrease after administration of triptans in
parallel with symptomatic relief [24, 25]. Serum CGRP levels are elevated
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interictally in chronic migraine and to a lesser extent in episodic migraine [26].
Lastly, intravenous infusion of CGRP triggers attacks in migraineurs that are
indistinguishable from spontaneous attacks [27, 28].
Antagonism of the CGRP pathway has been pursued as a new strategy for
both acute and preventive treatment of migraine with promising results [12].
Clinical trials
The CGRP mechanism can be antagonized by targeting either the peptide or its
receptor with either small molecule antagonists or monoclonal antibodies. This
was first attempted for acute treatment of migraine. Several antagonists of the
CGRP receptor including olcegepant (BIBN 4096 BS), telcagepant (MK-0974),
MK-3207, BI 44370 TA, and BMS-927711 resulted in significantly higher pain-
free rates at 2 h when compared to placebo [29–33]. Unfortunately, develop-
ment was complicated by pharmacokinetic issues and for telcagepant and MK-
3207 by hepatotoxicity. Ubrogepant is still under development for acute treat-
ment [34] and atogepant for prevention (NCT02848326). Despite initial set-
backs, these clinical trials have provided the proof of principle that targeting the
CGRP pathway can effectively treat migraine.
Telcagepant was also investigated for prevention of episodic migraine [35].
Subjects with 3 to 14 days of headache during a 4-week baseline period were
randomized to receive a daily dose of telcagepant 140 or 280mg or placebo for
12 weeks. The trial was terminated prematurely due to hepatotoxicity concerns;
13 patients in the telcagepant group and none in the placebo arm had de-
rangement of liver function tests greater than three times the upper limit of
normal. At the time of termination, all patients (n = 660) had been randomized,
most had completed 1month of treatment (n = 593), and some had completed
2 months of treatment (n = 312). Efficacy analysis could not be performed as
originally planned, but the data suggested a reduction in the primary efficacy
endpoint, mean monthly headache days, in the telcagepant groups compared
to placebo after 1 month.
Monoclonal antibodies have been used increasingly for treatment of neuro-
logical disorders [36, 37], and migraine has been no exception. Monoclonal
antibodies have a long half-life that makes them suitable for therapies requiring
chronic activity such as migraine prevention. Furthermore, their long duration
of action allows for less frequent dosing, e.g., once or twice monthly. Finally,
antibodies are highly specific, allowing for highly selective targeting of either
CGRP or its receptor.
Four monoclonal antibodies are currently in development for migraine
prevention: three against CGRP itself: galcanezumab (LY2951742),
eptinezumab (ALD403), and fremanezumab (TEV-48215) and one against the
CGRP receptor erenumab (AMG-334). Results from phase II trials have been
published for all four compounds (Table 1), and phase III trials are underway or
completed. Phase III results have not been published to date.
Galcanezumab (LY2951742): The first phase II clinical trial results to be
published were for Eli-Lilly’s galcanezumab [38]. This study randomized pa-
tients with episodicmigraine (4 to 14 headache days in 4-week baseline period)
to galcanezumab 150 mg subcutaneously versus placebo every 2 weeks for
12 weeks. Primary efficacy endpoint was the change in number of migraine
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days during the third 4-week treatment period (weeks 9–12) compared to the
baseline period. The mean change in migraine headache days was significantly
different in the galcanezumab group compared to the placebo group (−4.2
versus −3.0 days, respectively; least squares mean difference 1.2, p = 0.0030).
Eptinezumab (ALD-403): Alder Biopharmaceuticals took a slightly different
approach with eptinezumab, reasoning that intravenous administration would
result in rapidly efficacious dosing with immediate physiological effect. Patients
with episodic migraine (5 to 14 headache days in 4-week baseline period) were
randomized to either a single dose of monthly intravenous eptinezumab
1000 mg or placebo. The primary efficacy endpoint was the change in number
of migraine days during weeks 5–8 compared to the baseline period. With a
one-sided p value (pre-specified), eptinezumab resulted in significantly fewer
migraine days compared to placebo (−5.6 versus −4.6 days, respectively; dif-
ference 1.0, p = 0.0306) [39].
fremanezumab (TEV-48215 or LBR-101): Teva Pharmaceuticals investigated
fremanezumab in two separate trials for patients with either high-frequency
episodic migraine or chronic migraine [40, 41]. Patients with 8 to 14 headache
days in 4-week baseline period were randomized to subcutaneous injections of
either fremanezumab 225 or 675 mg or placebo every 4 weeks for 12 weeks.
Primary efficacy endpoint was the change in number of migraine days during
the third 4-week treatment period (weeks 9–12) compared to the baseline
period. The least square mean reduction in migraine days was significantly
greater compared to placebo for both the fremanezumab 225mg (−6.27 versus
−3.46 days; difference 2.81 days, p G 0.0001) and 675 mg doses (−6.09 versus
−3.46 days; difference 2.64 days, p G 0.0001). Of note, in contrast to the
previous two studies, patients were not excluded for use of a migraine preven-
tive; use of one preventive was allowed provided the dose had been stable for
2 months prior to screening.
For the chronicmigraine trial, patients were randomized to either placebo or
one of two fremanezumab doses given every 4 weeks for 12 weeks: 675 mg
loading dose followed by two 225 mg doses or three doses of 900 mg. Primary
efficacy endpoint was change in hours of headache of any severity during the
third 4-week treatment period (weeks 9–12) compared to the baseline period.
The least square mean reduction in headache hours of any severity was signif-
icantly greater compared to placebo for both the fremanezumab 675 mg/
225 mg /225 mg (−59.8 versus −37.1 h; difference 22.7 h, p = 0.0386) and
900mg doses (−67.5 versus −37.1 h; difference 30.4 h, p = 0.0057). Use of up to
two preventives was permitted provided the doses were stable for at least
3 months. Of note, although chronic migraine is defined as 15 or more days of
headache per month, the mean number of headache days per month in the
study population was approximately 16. Thus, the results may not be general-
izable to patients with daily or near daily headache.
Erenumab (AMG-334): Lastly, Amgen has developed amonoclonal antibody
against the CGRP receptor, erenumab, in contrast to the other three antibodies
that are targeted at the CGRPmolecule itself. Patients with episodic migraine (4
to 14 headache days in 4-week baseline period) were randomized to either
placebo or one of three doses of erenumab (7, 14, or 70 mg) subcutaneously
every 4 weeks for 12 weeks. Primary efficacy endpoint was the change in
number of migraine days during the third 4-week treatment period (weeks 9–
12) compared to the baseline period. The least squaremean change inmigraine
27 Page 6 of 11 Curr Treat Options Neurol (2017) 19: 27
headache days was significantly different from the placebo group only for the
highest dose, erenumab 70 mg (−3.4 versus −2.3 days; difference 1.1 days,
p = 0.021) [42].
Safety and tolerability
Initial safety and tolerability data from phase II trials appears excellent for the
anti-CGRP monoclonal antibodies. No clinically significant change in vitals or
ECGs was observed. Importantly, no change in hepatic enzymes judged to be
treatment-related was seen with any of the monoclonal antibodies, in contrast
to the small molecule CGRP receptor antagonists telcagepant and MK-3207.
Adverse events were reported in a similar proportion of patients in the placebo
and treatment groups. The most common treatment-related adverse event was
injection site reaction of mild to moderate severity with subcutaneous injec-
tions; no intravenous infusion reactions were seen with eptinezumab. No
treatment-related serious adverse events were reported.
Although all the monoclonal antibodies have been humanized to reduce
immunogenicity, antibodies against these treatments can still form. All studies
assessed for the presence of anti-drug antibodies, which were sometimes pres-
ent before treatment. Anti-drug antibodies did not appear to affect drug con-
centration, efficacy, or adverse events.
All of the phase II trials administered treatment for 3 months with the
exception of eptinezumab, which administered a single monthly dose. Thus,
long-term safety is entirely unknown at this time. Open-label treatment phases
lasting 1 year or longer will provide essential, longer-term safety and tolerability
data.
The full range of CGRP’s physiologic functions is complex [43]. CGRP is a
potent vasodilator, and thus, a theoretical risk exists that CGRP blockade could
hinder vasodilation in physiologically appropriate situations such as cardiac or
cerebrovascular ischemia. Indeed, animal data suggests that CGRP plays a
protective role against cardiac ischemia, cerebrovascular ischemia, and reper-
fusion injury and vasospasm after subarachnoid hemorrhage [44•]. Addition-
ally, since antibodies have a relatively long half-life, any untoward effects could
not be quickly reversed.
Although no cardiovascular effects have been seen to date, the incidence of
cardiovascular or cerebrovascular disease is very low in the populations studied;
the mean age in the various trials ranged from 39 to 43 years. Much larger
populations would be needed to see the effect of CGRP blockade on very rare
events, and this would likely only be achievedwith post-marketing surveillance.
Furthermore, the potential for long-term effects of chronic CGRP inhibition
over years even without overt ischemia is entirely unknown.
Lastly, CGRP receptors are found outside of the nervous and vascular
systems, including in the adrenal glands, kidneys, pancreas, and bone. The
effect of chronic CGRP antagonism on other organs is unknown.
Discussion
Antagonists of the CGRP pathway comprise the first class of therapeutics
targeted at a migraine-specific mechanism, and the use of monoclonal
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antibodies is a novel approach in migraine prevention. All four monoclo-
nal antibodies in development have had positive phase II trials. In addi-
tion, it appears that efficacy might be seen more quickly with these
antibodies than with current preventive options, which typically require up
to 8 weeks of treatment, although this must be interpreted with caution. As
prespecified additional endpoints, the primary outcome variable was also
measured after the first and second treatment cycles (at weeks 4 and 8) in
both of the fremanezumab trials; a significantly greater reduction com-
pared with placebo was seen at both time points. Likewise, the erenumab
70 mg group, the only dose significantly different from placebo at
12 weeks, also showed a significant reduction in migraine days compared
to placebo at weeks 4 and 8. A single dose of eptinezumab resulted in a
significant reduction in migraine days in weeks 5 to 8, albeit with a one-
side p value. A post hoc analysis conducted for the fremanezumab chronic
migraine trial showed a significant reduction in number of headache hours
compared to placebo within the first week of treatment [45].
Monoclonal antibodies are large molecules that cross the blood-brain
barrier in a small ratio of 1:1000 [46], although in individual patients,
the ratio may favor penetration more [47]. Thus, their site of action in
migraine prevention is unclear. Additionally, while most acute treat-
ments for migraine have the potential to worsen migraine with frequent
use, antagonism of the CGRP pathway is effective both acutely and
chronically for prevention. Thus, the efficacy of CGRP antagonists raises
interesting questions about migraine pathophysiology and much remains
to be understood.
The cost of treatment, once the monoclonal antibodies become commer-
cially available, will certainly be high. In a healthcare system of limited re-
sources, this cost will need to be balanced with the magnitude of benefit. The
primary endpoint of migraine days is not a useful clinical measure since it
presents the average of those that do well and those that do poorly. In line with
this, trials also analyzed the 50, 75, or 100% responder rates, the proportion of
patients achieving the respective reduction in the primary outcome, either as
exploratory endpoints or in post hoc analyses. Most trials found significantly
higher responder rates compared with placebo at week 12 and often earlier. An
important task will be to attempt to identify patients more likely to benefit so
personalized therapy can begin to offset the cost of the treatments by mini-
mizing the number of patients treated who have no useful response.
An important group of patients, those that failed more than two preventive
categories, was largely excluded from the trials, and thus, it is unknown what
benefit this population would derive. While their exclusion from initial trials
may be warranted to maximize sensitivity to detecting efficacy, from a clinical
perspective, this group is of particular interest. Patients seen at specialty head-
ache centers are often medically partially refractory, having failed a number of
preventives with limited remaining options. This group potentially stands to
benefit the most from a novel, migraine-specific mechanism.
While the long-term safety profile of the anti-CGRP antibodies remains to be
seen, a well-tolerated treatment targeting a migraine-specific mechanism for the
first time represents the most significant advance in migraine therapy in de-
cades. A new era of migraine prevention is on the horizon, an exciting devel-
opment for clinicians and patients alike.
27 Page 8 of 11 Curr Treat Options Neurol (2017) 19: 27
Compliance with Ethical Standards
Conflict of Interest
Amy R. Tso declares no conflict of interest.
Peter J. Goadsby has received grants and personal fees from Amgen and Eli-Lilly and Company and personal fees
from Alder Biopharmaceuticals, Novartis, Teva Pharmaceuticals during the conduct of the study. Dr. Goadsby has
also received personal fees from Akita Biomedical, Avanir Pharma, Cipla Ltd., Dr. Reddy’s Laboratories, Electrocore
LLC, Pfizer Inc., Promius Pharma, Quest Diagnostics, Scion, Trigemina Inc., MedicoLegal work, Journal Watch, Up-
to-Date, Oxford University Press, Massachusetts Medical Society, outside the submitted work. In addition, Dr.
Goadsby has a patent Magnetic stimulation for headache pending to eNeura.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Open Access
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction
in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
References and Recommended Reading
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Goadsby PJ, Lipton RB, Ferrari MD.
Migraine—current understanding and treatment.
N Engl J Med. 2002;346:257–70.
2. Goadsby PJ, Sprenger T. Current practice and fu-
ture directions in the management of migraine:
acute and preventive. Lancet Neurol. 2010;9:285–
98.
3. Humphrey PPA, Feniuk W, Perren MJ, Beresford IJM,
Skingle M,Whalley ET. Serotonin andmigraine. Ann N
Y Acad Sci. 1990;600:587–98.
4. Graham JR, Wolff HG. Mechanism of migraine head-
ache and action of ergotamine tartrate. Arch Neurol
Psychiatr. 1938;39:737–63.
5.•• Goadsby PJ, Holland PR, Martins-Oliveira M, Hoff-
mann J, Schankin C, Akerman S. Pathophysiology of
Migraine—a disorder of sensory processing. Physiol
Rev. 2017;97:553–622.
Comprehensive review of migraine pathophysiology.
6. Disease GBD, Injury I, Prevalence C. Global, regional,
and national incidence, prevalence, and years lived
with disability for 310 diseases and injuries, 1990–
2015: a systematic analysis for the Global Burden of
Disease Study 2015. Lancet. 2016;388(10053):1545–
602.
7. Raval AD, Shah A. National trends in direct health care
expenditures among US adults with migraine: 2004 to
2013. J Pain. 2017;18:96–107.
8. Munakata J, Hazard E, Serrano D, Klingman D,
Rupnow MF, Tierce J, et al. Economic burden of trans-
formed migraine: results from the American Migraine
Prevalence and Prevention (AMPP) Study. Headache.
2009;49:498–508.
9. Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC,
Varon SF, Maglinte GA, et al. Patterns of use and rea-
sons for discontinuation of prophylactic medications
for episodic migraine and chronic migraine: results
from the second international burden of migraine
study (IBMS-II). Headache. 2013;53(4):644–55.
10. Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN,
Devine EB. Adherence to oral migraine-preventive
Curr Treat Options Neurol (2017) 19: 27 Page 9 of 11 27
medications among patients with chronic migraine.
Cephalalgia. 2015;35(6):478–88.
11. Tso AR, Goadsby PJ. New targets for migraine therapy.
Curr Treat Options Neurol. 2014;16:318.
12. Goadsby PJ. Bench to Bedside Advances in the twenty-
first Century for primary headache
disorders—migraine treatments for migraine patients.
Brain. 2016;139:2571–7.
13. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM.
Alternative RNA processing in calcitonin gene expres-
sion generates mRNAs encoding different polypeptide
products. Nature. 1982;298:240–4.
14. Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW,
Sawchenko PE, Rivier J, et al. Production of a novel
neuropeptide encoded by the calcitonin gene via tissue
specific RNA processing. Nature. 1983;304:129–35.
15.•• Edvinsson L. CGRP receptor antagonists and antibod-
ies against CGRP and its receptor in migraine treat-
ment. Br J Clin Pharmacol. 2015;80:193–9.
Comprehensive review of CGRP pharmacology.
16. Eftekhari S, Edvinsson L. Possible sites of action of the
new calcitonin gene-related peptide receptor antago-
nists. Ther Adv Neurol Disord. 2010;3:369–78.
17. Hou M, Kanje M, Longmore J, Tajti J, Uddman R,
Edvinsson L. 5-HT1B and 5-HT1D receptors in the hu-
man trigeminal ganglion: co-localization with
calitonin gene-related peptide, substance P and nitric
oxide synthase. Brain Res. 2001;909:112–20.
18. Van Rossum D, Hanisch UK, Quirion R. Neuroana-
tomical localization, pharmacological characterization
and functions of CGRP, related peptides and their
receptors. Neurosci Biobehav Rev. 1997;21:649–78.
19. Tschopp FA, Henke H, Petermann JB, Tobler PH,
Janzer R, Hokfelt T, et al. Calcitonin gene-related
peptide and its binding sites in the human central
nervous system and pituitary. Proc Natl Acad Sci U
S A. 1985;82:248–52.
20. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J,
Thompson N, et al. RAMPs regulate the transport and
ligand specificity of the calcitonin-receptor-like recep-
tor. Nature. 1998;393:333–9.
21. Wimalawansa SJ. Calcitonin gene-related peptide and
its receptors: molecular genetics, physiology, patho-
physiology, and therapeutic potentials. Endocr Rev.
1996;17:533–85.
22. Edvinsson L, Ekman R, Jansen I, McCulloch J, Uddman
R. Calcitonin gene-related peptide and cerebral blood
vessels: distribution and vasomotor effects. J Cereb
Blood Flow Metab. 1987;7:720–8.
23. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide
release in the extracerebral circulation of humans dur-
ing migraine headache. Ann Neurol. 1990;28:183–7.
24. Goadsby PJ, Edvinsson L. The trigeminovascular sys-
tem and migraine: studies characterizing cerebrovas-
cular and neuropeptide changes seen in humans and
cats. Ann Neurol. 1993;33:48–56.
25. Juhasz G, Zsombok T, Jakab B, Nemeth J,
Szolcsanyi J, Bagdy G. Sumatriptan causes parallel
decrease in plasma calcitonin gene-related peptide
(CGRP) concentration and migraine headache
during nitroglycerin induced migraine attack.
Cephalalgia. 2005;25:179–83.
26. Cernuda-Morollon E, Larrosa D, Ramon C, Vega J,
Martinez-Camblor P, Pascual J. Interictal increase of
CGRP levels in peripheral blood as a biomarker for
chronic migraine. Neurology. 2013;81:1191–6.
27. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK,
Sperling B, Olesen J. CGRPmay play a causative role in
migraine. Cephalalgia. 2002;22:54–61.
28. Hansen JM, Hauge AW, Olesen J, AshinaM. Calcitonin
gene-related peptide triggers migraine-like attacks in
patients with migraine with aura. Cephalalgia.
2010;30:1179–86.
29. Connor KM, Shapiro RE, Diener HC, Lucas S, Kost J,
Fan X, et al. Randomized, controlled trial of
telcagepant for the acute treatment of migraine. Neu-
rology. 2009;73:970–7.
30. Diener H-C, Barbanti P, Dahlof C, Reuter U, Habeck J,
Podhorna J. BI 44370 TA, an oral CGRP antagonist for
the acute treatment of migraine attacks: results from a
phase II study. Cephalalgia. 2011;31:573–84.
31. Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge J,
Bachman R, et al. Randomized controlled trial of the
CGRP receptor antagonist, MK-3207, in the acute
treatment of migraine. Cephalalgia. 2011;31:712–22.
32. Marcus R, Goadsby PJ, Dodick D, Stock D, Manos
G, Fischer TZ. BMS-927711 for the acute treat-
ment of migraine: a double-blind, randomized,
placebo controlled, dose-ranging trial.
Cephalalgia. 2014;34:114–25.
33. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D,
Meier U, et al. Calcitonin gene-related peptide receptor
antagonist BIBN 4096 BS for the acute treatment of
migraine. N Engl J Med. 2004;350:1104–10.
34. Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY,
Bachman R, et al. A phase IIb randomized, double-
blind, placebo-controlled trial of ubrogepant for the
acute treatment of migraine. Cephalalgia.
2016;36:887–98.
35. Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver
J, Fan X, et al. Randomized controlled trial of the CGRP
receptor antagonist telcagepant for migraine prevention.
Neurology (Minneap). 2014;83:958–66.
36. Foltz IN, Karow M, Wasserman SM. Evolution and
emergence of therapeutic monoclonal antibodies:
what cardiologists need to know. Circulation.
2013;127(22):2222–30.
37. Lutterotti A, Martin R. Getting specific: monoclonal
antibodies in multiple sclerosis. Lancet Neurol.
2008;7(6):538–47.
38. Dodick DW, Goadsby PJ, Spierings ELH, Scherer JC,
Sweeney SP, Grayzel DS. CGRP monoclonal antibody
LY2951742 for the prevention of migraine: a phase 2,
randomized, double-blind, placebo-controlled study.
Lancet Neurol. 2014;13:885–92.
39. Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB,
Olesen J, Ashina M, et al. Randomized, double-blind,
placebo-controlled, phase II trial of ALD403, an anti-
27 Page 10 of 11 Curr Treat Options Neurol (2017) 19: 27
CGRP peptide antibody in the prevention of frequent
episodic migraine. Lancet Neurol. 2014;13:1100–7.
40. Bigal ME, Dodick DW, Rapoport AM, Silberstein SD,
Ma Y, Yang R, et al. Safety, tolerability, and efficacy of
TEV-48125 for preventive treatment of high-frequency
episodic migraine: a multicentre, randomized, double-
blind, placebo-controlled, phase 2b study. Lancet
Neurol. 2015;14:1081–90.
41. Bigal ME, Edvinsson L, Rapoport AM, Lipton RB,
Spierings ELH, Diener H-C, et al. Safety, tolerability,
and efficacy of TEV-48125 for preventive treatment of
chronic migraine: a multicentre, randomized, double-
blind, placebo-controlled, phase 2b study. Lancet
Neurol. 2015;14:1091–100.
42. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter
U, Ashina M, et al. A randomised, double-blind, pla-
cebo-controlled, phase 2 study to evaluate the efficacy
and safety of AMG 334 for the prevention of episodic
migraine. Lancet Neurol. 2016;15:382–90.
43. Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Cal-
citonin gene-related peptide: physiology and patho-
physiology. Physiol Rev. 2014;94(4):1099–142.
44.• MaassenVanDenBrink A, Meijer J, Villalon CM, Ferrari
MD. Wiping out CGRP: potential cardiovascular risks.
Trends Pharmacol Sci. 2016;37(9):779–88.
Summary of cardiovascular and cerebrovascular effects of CGRP.
45. Bigal ME, Dodick DW, Krymchantowski AV,
VanderPluym JH, Tepper SJ, Aycardi E, et al. TEV-
48125 for the preventive treatment of chronic
migraine—efficacy at early time points. Neurology
(Minneap). 2016;87:41–8.
46. Felgenhauer K. Protein size and cerebrospinal fluid
composition. Klin Wochenschr. 1974;52(24):1158–64.
47. Pittock SJ, Lennon VA, McKeon A, Mandrekar J,
Weinshenker BG, Lucchinetti CF, et al. Eculizumab in
AQP4-IgG-positive relapsing neuromyelitis optica
spectrum disorders: an open-label pilot study. Lancet
Neurol. 2013;12(6):554–62.
Curr Treat Options Neurol (2017) 19: 27 Page 11 of 11 27
